Acute myeloid leukemia (AML) is a heterogeneous disease, and AML with normal karyotype (AML-NK) is categorized as an intermediate-risk group based on cytogenetic stratification. However, molecular analyses successfully identified biomarkers that further allowed dissecting clinically meaningful subgroups. In AML-NK, acquired mutations with prognostic relevance were identified for FLT3, CEBPA, and NPM1.
1 FLT3-internal tandem duplication (ITD) mutations were associated with short relapse-free and overall survival, whereas mutations in CEBPA or NPM1Fwithout concomitant FLT3-ITDFhad a more favorable outcome. 2 Here, we present gene expression profiles of 251 de novo AML-NK cases. In three centers, microarray analyses were performed to delineate robust expression signatures for molecular markers and to elucidate the disturbance of cellular growth, proliferation, and differentiation processes in this disease.
All samples were obtained from untreated AML patients at the time of diagnosis (Dresden, n ¼ 78; Munich, n ¼ 96; Ulm, n ¼ 77). Cells were collected from the purified fraction of mononuclear cells after Ficoll density centrifugation. Each laboratory performed its routine diagnostic algorithms, including the characterization of molecular markers NPM1, FLT3, and CEBPA, as reported earlier. [2] [3] [4] [5] [6] Only AML samples with a NK were included. For conventional chromosome banding analysis, the median number of analyzed metaphases was 20 per case. The study design adhered to the tenets of the Declaration of Helsinki and was approved by ethics committees of the participating institutions before its initiation.
In all, 251 high-quality whole-genome Affymetrix HG-U133 Plus 2.0 gene expression profiles were generated in the three centers (Supplementary Tables S1-S3 ). Microarray analyses were performed following a standardized assay workflow as reported earlier (Supplementary Figure S1) . 7, 8 To visualize gene expression patterns, we applied hierarchical clustering and principal component analyses (see Supplementary Information) . Gene expression data were analyzed using GeneMaths XT Version 2.1 (Applied Maths, St-Martens-Latem, Belgium) and Partek Genomics Suite Version 6.4 (Partek Inc., St Louis, MO, USA). Microarray raw data and clinical patient annotation were deposited online in the Gene Expression Omnibus database under the accession number GSE15434. First, we focused on nucleophosmin gene (NPM1) mutations, the most frequent genetic lesion described in de novo adult AML-NK to date. 9 Gene expression signatures for 138 NPM1-mutated cases were compared to profiles of 113 NPM1-unmutated cases and a strong differential gene expression pattern was observed (Figure 1a ). This signature also showed a substantial overlap to the predictive NPM1 mutation signatures as published by Alcalay et al., 10 and Verhaak et al.
11
Our analyses confirmed 16/20 10 and 17/18 11 common genes in comparison to the published sets ( Supplementary  Figures S2 and S3 ). With respect to the robustness of the differential gene expression signatures in NPM1-mutated cases across the participating laboratories, a consensus signature of 301 unique probe sets that belonged to the top-500 signature of a single center could be verified in both other centers (Figures 1b and c) .
Supervised classification analyses by 10-fold cross-validation resulted in 495% prediction accuracy of NPM1 mutation status (Supplementary Table S5 ). The sensitivity was very high for the positive detection of NPM1-mutated cases (497%). By using a resampling approach (100 iterations) and splitting the complete data into training (n ¼ 170) and test (n ¼ 81) sets, the high prediction accuracy was confirmed (Supplementary Table S6 ). The most frequently selected candidates with higher expression in NPM1-mutated cases comprised : HOXA1, HOXA2, HOXA3,  HOXA4, HOXA5, HOXA6, HOXA7, HOXA9, HOXA10,  HOXB2, HOXB3, HOXB4, HOXB5, HOXB6, HOXB7, HOXB9 , MEIS1, and PBX3. Lower expression in NPM1-mutated cases was observed for ABCB1, BAALC, MN1, MLLT3, or SPARC. A Gene Set Enrichment Analysis considering Gene Ontology (GO) terms 12, 13 revealed the following biological processes to be significantly associated with NPM1-mutated cases (Supplementary Table S7 The table depicts the overlap of three top-500 differentially expressed gene lists, which were calculated within a specific center according to NPM1 mutation status (Supplementary Table S3 ). The union of all probe sets in the last column gives a signature of 301 unique probe sets, termed as multicenter NPM1 consensus signature (Supplementary Table S4 ). (c) The consensus signature of 301 probe sets is further explored by principal component analysis. The 251 cases are colored according to NPM1 mutation status, and each sphere represents a single gene expression profile based on the common 301 overlapping probe sets. Detailed information on the probe sets is available online.
Letters to the Editor included HOXA2, HOXA3, HOXA5, HOXA7, HOXA9, HOXA10, HOXB2, HOXB3, HOXB4, HOXB5, HOXB6, HOXB7, and HOXB9. Thus, several HOX genes were overlapping with the NPM1 signature, albeit with an inverse correlation, that is, HOX genes with relative overexpression in NPM1-mutated AML-NK showed low expression in CEBPAmutated cases (Supplementary Figure S5) . GO terms significantly associated with CEBPA-mutated cases showed multiple processes to be low in CEBPA-mutated cases (Supplementary  Table S8 ): positive regulation of cell differentiation (GO:0045597) or regulation of myeloid cell differentiation (GO:0045637). The Gene Set Enrichment Analysis also pointed toward a perturbation of the MAP kinase pathway in CEBPAmutated cases with affected processes, such as regulation of MAP kinase activity (GO:0043405) and MAPKKK cascade (GO:0000165). On integration of the signatures for NPM1 and CEBPA, three clusters emerged (Figure 2a) . One cluster contained NPM1-mutated cases with wild-type CEBPA, and in the NPM1-unmutated cluster CEBPA-mutated cases were further distinct and separated (Figure 2b) . A classification analysis taking both NPM1 and CEBPA status into account showed accuracies of 492%, with sensitivities of predicting NPM1 wild-type/CEBPAmutated cases with 475.9% sensitivity (Supplementary Tables  S12 and S13) .
Interestingly, in our cohort, at least one sample was indicative of a 'silenced-CEBPA' phenotype.
14 This case was confirmed to be negative for the mutation, but clustered together with Detailed information on the probe sets and analysis workflow is available online. Note: one case harboring concomitant NPM1 and CEBPA mutations was excluded from this analysis. Figure S6) . By applying the predictive signature proposed by Wouters and colleagues, we observed the characteristic aberrant overexpression of T-cell genes, whereas CEBPA expression was not detectable. To our knowledge, this is the first independent validation of this proposed novel subset of AML with partial T-lymphoid phenotype. 15 A third analysis focused on the fms-related tyrosine kinase 3 gene (FLT3) ITD mutation status. In the single-marker analysis including all 251 AML-NK cases, a clear signature and associated biological GO terms were observed (Supplementary Figure S7 ; Supplementary Table S9) , also confirming recent data from Bullinger and colleagues, who presented a 20-gene FLT3-ITD predictor for AML-NK (Supplementary Figure S8) . This signature was also robust across different chip platforms, since the data by Bullinger et al. 16 was generated using a spotted cDNA microarray.
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With respect to classifying AML-NK samples based on gene expression data, we observed lower accuracy rates for the single-marker FLT3-ITD in comparison to NPM1 or CEPBA. The sensitivity to predict FLT3-ITD positivity was only around B70.0% (Supplementary Tables S14 and S15 ). However, this result is in agreement with recent data from Verhaak et al., 17 who reported a positive predictive value for FLT3-ITD aberrations of 77%. As many FLT3-ITD cases were intercalating with FLT3 wild-type cases (Supplementary Figure S7) , one can speculate that a FLT3-ITD signature might become more robust on further evaluation of the ratio of the mutated allele in comparison to the wild-type allele. Yet, using expression microarrays as a platform to rely on accurately determining the FLT3-ITD status seems more error prone in comparison to standard methods.
In conclusion, our gene expression profiling study shows robust signatures for AML-NK with NPM1, CEBPA, or FLT3-ITD mutations. Signatures for NPM1 predicted mutations with very high accuracies and defined biological singularity of molecularly characterized AML subtypes, which is in line with the new WHO classification that categorizes these subtypes as provisional entities. 18 This is an important result as many microarray gene expression signatures are difficult to reproduce given the complexity of microarray-based expression studies. 19 In contrast, FLT3-ITD does not provide a clear-cut AML subtype according to respective gene expression data. Our results further allowed novel biological insights into perturbed pathways associated with molecular markers in AML-NK. Therefore, we support to refine the classification of AML with NK as a specific entity also by incorporating molecular risk-based gene expression signatures.
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A Kohlmann 1 , L Bullinger
In this study, to adequately dissect the molecular network downstream of NFI-A, we performed gene expression profiling of normal human uncommitted CD34
þ HPCs efficiently expressing exogenous NFI-A at high level. CD34
þ HPCs were purified from fresh cord blood obtained from healthy donors, pre-stimulated in serum-free medium supplemented with SCF 50 ng/ml, Flt3 ligand 50 ng/ml, IL-3 20 ng/ml and TPO 20 ng/ml overnight and transduced with a lentiviral vector encoding NFI-A or a control empty Vector as previously described. 2 Forty-eight hours after transduction, GFP þ cells were sorted using FACSAria instrument (BD Biosciences, San Josè, CA, USA), subjected to total RNA extraction and hybridized on Agilent whole human genome oligo microarray (No. G4112F; Agilent Technologies, Palo Alto, CA, USA; detailed protocols are summarized in Supplementary Information).
To quantify the resulting amount of NFI-A in both the Vector and NFI-A samples, we performed a real-time PCR using primers specific for NFI-A (primers used are listed in Supplementary  Table S2 ). As shown in Figure 1a , the relative amount of NFI-A is greatly increased in the NFI-A-transduced compared to Vector-infected cells. Microarray results were then analyzed by using the GeneSpring GX 10 software (Agilent Technologies). Data transformation was applied to set all the negative raw values at 1.0, followed by a Quantile normalization. A filter on low gene expression was used to keep only the probes expressed in at least one sample (flagged as Marginal or Present). Expressed genes having a fold change of 41.5 between the Vector and NFI-A samples were selected. Interestingly, numerous genes were upregulated in the exogenous NFI-A-expressing sample, whereas relatively less genes were downregulated (for the complete raw and normalized data see Supplemental Table S1 ), suggesting that NFI-A per se behaves both as a transcriptional activator and repressor in undifferentiated CD34 þ cells. On careful analysis and classification of the data, we noted among the modulated genes a consistent number of erythroid genes. Many of these genes reflected an intermediate-to-mature erythroid developmental stage, and were in general accordance with recent genome-wide analyses performed on a variety of in vitro erythroid differentiation systems. [6] [7] [8] Out of this extensive number of potential target genes, a list of 27 genes corresponding to well-characterized erythroid-affiliated genes was used for cluster analysis of samples using the Euclidean distance as a measure of similarity ( Figure 1b) . As shown in Figure 1b , the NFI-A cells displayed considerable induction of erythroid cell membrane molecules, including CDH1, the Rh antigen family (RHAG; RHC/RHD), SLC4A1, AQP1, ADD3 and SPTB; molecules involved in the hemoglobin biosynthetic pathway, including ALAS2 and globin chains HBB, HBA and HBD; growth factors and growth factor receptors, including INHBA, EFBN2 and IGF2; signal transduction molecules, including JAK2, AKT2 and GAB1; transcription factors or DNA-binding proteins, including JUNB, HOXB8, KLF2, SSBP3 and TRIM10;
